Abiopharma

🔍 Chang Kochi (Director)

Company: YD Bio Ltd (YDES)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 2,081 shares of Ordinary Shares (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,081.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,081 shares of Restricted Share Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,081.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F2
• Acquired 2,081 shares of Restricted Share Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.
• F2: The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.
• F3: The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").